{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:58:55Z","timestamp":1775617135499,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cellimm.2024.104901","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T02:16:11Z","timestamp":1733364971000},"page":"104901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["P2RX1-blocked neutrophils induce CD8+ T cell dysfunction and affect the immune escape of gastric cancer cells"],"prefix":"10.1016","volume":"408","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2024.104901_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cellimm.2024.104901_bb0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2024.104901_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0426","article-title":"Effect of S-1 plus Oxaliplatin compared with fluorouracil, Leucovorin plus Oxaliplatin as perioperative chemotherapy for locally advanced, Resectable gastric Cancer: a randomized clinical trial","volume":"5","author":"Yu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cellimm.2024.104901_bb0020","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s00595-020-02222-0","article-title":"Current status of conversion surgery for stage IV gastric cancer","volume":"51","author":"Kinoshita","year":"2021","journal-title":"Surg. Today"},{"key":"10.1016\/j.cellimm.2024.104901_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.cellimm.2024.104901_bb0030","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-20-4691","article-title":"Camrelizumab combined with chemotherapy followed by Camrelizumab plus Apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Peng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2024.104901_bb0035","article-title":"Recent Progress and future perspectives of immunotherapy in advanced gastric Cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2024.104901_bb0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.cellimm.2024.104901_bb0055","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cellimm.2024.104901_bb0060","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cncr.31855","article-title":"Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China","volume":"125","author":"Huang","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.cellimm.2024.104901_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-35723-8_1","article-title":"Neutrophils in the tumor microenvironment","volume":"1224","author":"Wu","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41389-020-00249-z","article-title":"CXCL5 promotes gastric cancer metastasis by inducing epithelial-mesenchymal transition and activating neutrophils","volume":"9","author":"Mao","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.cellimm.2024.104901_bb0080","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-20-2870","article-title":"GLUT1 expression in tumor-associated neutrophils promotes lung Cancer growth and resistance to radiotherapy","volume":"81","author":"Ancey","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2024.104901_bb0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11302-021-09782-x","article-title":"Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils","volume":"17","author":"Audrito","year":"2021","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.cellimm.2024.104901_bb0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41467-020-20447-y","article-title":"Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2024.104901_bb0095","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41419-021-04028-5","article-title":"C5aR1-positive neutrophils promote breast cancer glycolysis through WTAP-dependent m6A methylation of ENO1","volume":"12","author":"Ou","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellimm.2024.104901_bb0100","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","article-title":"Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway","volume":"66","author":"Wang","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2024.104901_bb0105","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1038\/s41598-019-41742-9","article-title":"The ATP-gated P2X(1) ion channel contributes to the severity of antibody-mediated transfusion-related acute lung injury in mice","volume":"9","author":"El Mdawar","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellimm.2024.104901_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-022-03893-6","article-title":"Immune effects of PI3K\/Akt\/HIF-1alpha-regulated glycolysis in polymorphonuclear neutrophils during sepsis","volume":"26","author":"Pan","year":"2022","journal-title":"Crit. Care"},{"key":"10.1016\/j.cellimm.2024.104901_bb0115","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/cas.14888","article-title":"Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer","volume":"112","author":"Mori","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellimm.2024.104901_bb0120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejmech.2004.01.007","article-title":"Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist","volume":"39","author":"Kassack","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellimm.2024.104901_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002100100463","article-title":"NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors","volume":"364","author":"Braun","year":"2001","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0130","article-title":"Efficacy and safety of Camrelizumab in combination with docetaxel + S-1 sequenced by Camrelizumab + S-1 for stage III (PD-1+\/MSI-H\/EBV+\/dMMR) gastric Cancer: study protocol for a single-center, prospective, open-label","volume":"9","author":"Dong","year":"2022","journal-title":"Single-Arm Trial. Front Surg."},{"key":"10.1016\/j.cellimm.2024.104901_bb0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11302-020-09761-8","article-title":"Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy","volume":"17","author":"Zhang","year":"2021","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.cellimm.2024.104901_bb0140","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/1756-185X.13783","article-title":"P2 receptors mRNA expression profiles in macrophages from ankylosing spondylitis patients and healthy individuals","volume":"23","author":"Akhtari","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cellimm.2024.104901_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","article-title":"Neutrophils in cancer: heterogeneous and multifaceted","volume":"22","author":"Hedrick","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, Cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fonc.2020.00629","article-title":"Extracellular vesicles from gastric Cancer cells induce PD-L1 expression on neutrophils to suppress T-cell immunity","volume":"10","author":"Shi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellimm.2024.104901_bb0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41385-020-0297-3","article-title":"Intestinal epithelium-derived BATF3 promotes colitis-associated colon cancer through facilitating CXCL5-mediated neutrophils recruitment","volume":"14","author":"Lin","year":"2021","journal-title":"Mucosal Immunol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874924001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874924001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T10:37:28Z","timestamp":1737283048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874924001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S0008874924001047"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104901","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P2RX1-blocked neutrophils induce CD8+ T cell dysfunction and affect the immune escape of gastric cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104901"}}